SANTA CLARA, Calif., March 31, 2011 /PRNewswire/ — NewCardio,
Inc., (OTC Bulletin Board:
NWCI) a cardiovascular diagnostic solutions developer,
announced today that the Company has been invited to present the
results of a recent QTinno ® performance study at an upcoming
conference entitled “Cardiovascular Safety in Drug Development:
State-of-the-Art Assessments,” sponsored by the U.S. Food and Drug
Administration (FDA), the Cardiac Safety Research Consortium (CSRC)
and the Heart Rhythm Society. The conference will be held in
Washington, DC, on April 14-15, 2011.
The NewCardio study shows that QTinno’s intelligent ECG
selection and extraction provides accurate and optimized,
consistent and automated selection of electrocardiograms (ECGs)
from continuous 24 hour ECG recordings (Holter monitors), leading
to improved study power and a substantial reduction in the number
of study subjects needed to achieve the desired study power in
early Phase QT studies, to include Thorough QT studies (TQTS). The
results will be presented by Dr. Samuel George, NewCardio’s Senior
Medical Advisor, on behalf of NewCardio co-investigators Drs. Ihor
Gussak and Branislav Vajdic. The study was done in collaboration
with physician-scientists from a major pharmaceutical partner.
The study that will be presented at the FDA/CSRC/HRS conference
addresses the need for reliable and reproducible ECG selection from
Holter monitors. At present, the user visually selects three
10-second ECGs from the recording within five minutes of each
designated study time point, a labor-intensive approach that is
prone to error, increased variability and low reproducibility.
NewCardio developed a novel “intelligent” ECG selection algorithm
that evaluates the entire 10-minute window around the designated
time point and selects the lowest noise and most stable ECGs in the
window. The study shows NewCardio’s
‘/>”/>
SOURCE
